-
Atopic dermatitis : the therapeutic revolution is underway
Damsin Th , Libon F , Nikkels AF , Dezfoulian B
Rev Med Liege 2022, 77(5-6),377-383Abstract : The therapeutic prospects for patients with moderate to severe atopic dermatitis completely changed in 2017 with the arrival of the first targeted therapy, dupilumab. Achieving important clinical improvement scores are now possible with this monoclonal antibody directed against interleukins 4 and 13. Since that time, other agents such as tralokinumab arrived on the market, but also the small molecules called «JAK inhibitors» (upadacitinib, baricitinib, etc.). This article provides an inventory of the existing or imminent therapeutic options for atopic dermatitis.
